Moligo Technologies is rated 3 out of 5 in the category biotechnology. Read and write reviews about Moligo Technologies. We developed a new technology for enzymatic production of high quality, long and even functionalized DNA molecules, which will have a huge impact on industrial synthetic biology, precision diagnostics, therapeutics and nanotechnology. DNA oligonucleotides are commonly synthesized by solid phase, but after decades of fine-tuning and improvements in liquid handling, the upper limit of phosphoramidite-based oligo synthesis is now about 200-300 nucleotides, with further limitations in terms of purity and efficacy in presence of strong secondary structures or repeats. The advances and improvements in diagnostic and therapeutic systems based on nucleic acids are leading to a big and urgent need of highly pure and long DNA strands, and Moligo Technologies mission is to satisfy this necessity. In fact, thanks to our know-how, and to the capacity of experienced scientific and executive team, we are already able to synthesize, and very soon commercialize, single stranded oligonucleotides of thousands of bases with purity of about 99.9%.
Company size
1-10 employees
Headquarters
Bromma, Stockholm